Efficacy and safety of short course adjuvant trastuzumab combination chemotherapy in breast cancer

Background: The adjuvant short course 9-week trastuzumab combination therapy for human epidermal receptor 2 positive breast cancer patients may often be considered as a cost-effective and safe option and has important implications for the Indian subcontinent as well as other developing countries. Ho...

Full description

Bibliographic Details
Main Authors: Sachin S Hingmire, Mahesh B Sambhus, Dhananjay S Kelkar, Sujit Joshi, Purvish M Parikh, R Bharath
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2017-01-01
Series:South Asian Journal of Cancer
Subjects:
Online Access:http://journal.sajc.org/article.asp?issn=2278-330X;year=2017;volume=6;issue=2;spage=47;epage=50;aulast=Hingmire